These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 38270219)
1. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study. Gavriatopoulou M; Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Spiliopoulou V; Kanellias N; Eleutherakis-Papaiakovou E; Roussou M; Psarros G; Kastritis E; Dimopoulos MA; Terpos E Am J Hematol; 2024 Mar; 99(3):502-504. PubMed ID: 38270219 [No Abstract] [Full Text] [Related]
2. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study. Terpos E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Spiliopoulou V; Kostopoulos IV; Syrigou RE; Eleutherakis-Papaiakovou E; Gkolfinopoulos S; Tsitsilonis OE; Kastritis E; Dimopoulos MA Haematologica; 2024 Aug; 109(8):2594-2605. PubMed ID: 38356458 [TBL] [Abstract][Full Text] [Related]
3. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. Dimopoulos MA; Beksac M; Pour L; Delimpasi S; Vorobyev V; Quach H; Spicka I; Radocha J; Robak P; Kim K; Cavo M; Suzuki K; Morris K; Pompilus F; Phillips-Jones A; Zhou XL; Fulci G; Sule N; Kremer BE; Opalinska J; Mateos MV; Trudel S; N Engl J Med; 2024 Aug; 391(5):408-421. PubMed ID: 38828951 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771 [TBL] [Abstract][Full Text] [Related]
5. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Trudel S; McCurdy A; Louzada ML; Parkin S; White D; Chu MP; Kotb R; Mian H; Othman I; Su J; Khan A; Gul E; Reece D Nat Med; 2024 Feb; 30(2):543-551. PubMed ID: 38177852 [TBL] [Abstract][Full Text] [Related]
9. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Offidani M; Corvatta L; Morè S; Olivieri A Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900 [TBL] [Abstract][Full Text] [Related]
12. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legieć W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špička I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K; Lancet Haematol; 2022 Jun; 9(6):e403-e414. PubMed ID: 35550060 [TBL] [Abstract][Full Text] [Related]
13. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Kubo K; Hori M; Ohta K; Handa H; Hatake K; Matsumoto M; Hagiwara S; Ohashi K; Nakaseko C; Suzuki K; Ito S; Kinoshita G; Shelat SG; Miyoshi M; Takezako N Int J Hematol; 2020 Jan; 111(1):65-74. PubMed ID: 31701481 [TBL] [Abstract][Full Text] [Related]
14. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377 [TBL] [Abstract][Full Text] [Related]
15. Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. Belch A; Bahlis N; White D; Cheung M; Chen C; Shustik C; Song K; Tosikyan A; Dispenzieri A; Anderson K; Brown D; Robinson S; Srinivasan S; Facon T Cancer Med; 2020 Dec; 9(23):8923-8930. PubMed ID: 33049118 [TBL] [Abstract][Full Text] [Related]
16. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J; Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675 [TBL] [Abstract][Full Text] [Related]